Matthew Segar, MD

Dr. Segar is a cardiology fellow at The Texas Heart Institute. He graduated from Internal Medicine residency at UT Southwestern Medical Center and received his medical degree from the Indiana University School of Medicine. He also graduated with a degree in computer science with Honors from Bucknell University and a Masters of Science in Bioinformatics from Indiana University. His current research focuses on using machine learning and artificial intelligence to improve risk prediction and tailor medical therapies to identify and treat heart failure.

See Publications

Texas Heart Institute Positions

Current Projects

Education

  • Undergraduate:

    Bucknell University

  • Postgraduate:

    Indiana University

  • Medical School:

    Indiana University

  • Residency:

    The University of Texas Southwestern Medical Center

  • Fellowships:

    The Texas Heart Institute (Cardiovascular Disease)

Honors, Awards and Memberships

Publications

4862227 TU4G2TDX 1 alternatives-to-animal-experimentation 10 date desc Segar 37959 https://www.texasheart.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%225CSKUIVX%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Segar%20et%20al.%22%2C%22parsedDate%22%3A%222023-08-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bstrong%26gt%3BSegar%26lt%3B%5C%2Fstrong%26gt%3B%2C%20M.%20W.%2C%20Zhang%2C%20A.%2C%20Paisley%2C%20R.%20D.%20et%20al.%20%282023%29.%20Risk%20stratification%20in%20patients%20who%20underwent%20percutaneous%20left%20atrial%20appendage%20occlusion.%20%26lt%3Bi%26gt%3BAm%20J%20Cardiol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B200%26lt%3B%5C%2Fi%26gt%3B%2C%2050%26%23x2013%3B56.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.amjcard.2023.05.019%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.amjcard.2023.05.019%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Risk%20stratification%20in%20patients%20who%20underwent%20percutaneous%20left%20atrial%20appendage%20occlusion%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20W.%22%2C%22lastName%22%3A%22Segar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Allan%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20D.%22%2C%22lastName%22%3A%22Paisley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anish%22%2C%22lastName%22%3A%22Badjatiya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kaleb%20D.%22%2C%22lastName%22%3A%22Lambeth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karen%22%2C%22lastName%22%3A%22Mullins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mehdi%22%2C%22lastName%22%3A%22Razavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joanna%20E.%22%2C%22lastName%22%3A%22Molina-Razavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdi%22%2C%22lastName%22%3A%22Rasekh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohammad%22%2C%22lastName%22%3A%22Saeed%22%7D%5D%2C%22abstractNote%22%3A%22Left%20atrial%20appendage%20occlusion%20%28LAAO%29%20is%20effective%20in%20preventing%20thromboembolism.%20Risk%20stratification%20tools%20could%20help%20identify%20patients%20at%20risk%20for%20early%20mortality%20after%20LAAO.%20In%20this%20study%2C%20we%20validated%20and%20recalibrated%20a%20clinical%20risk%20score%20%28CRS%29%20to%20predict%20risk%20of%20all-cause%20mortality%20after%20LAAO.%20This%20study%20used%20data%20from%20patients%20who%20underwent%20LAAO%20in%20a%20single-center%2C%20tertiary%20hospital.%20A%20previously%20developed%20CRS%20using%205%20variables%20%28age%2C%20body%20mass%20index%20%5BBMI%5D%2C%20diabetes%2C%20heart%20failure%2C%20and%20estimated%20glomerular%20filtration%20rate%29%20was%20applied%20to%20each%20patient%20to%20assess%20risk%20of%20all-cause%20mortality%20at%201%20and%202%5Cu00a0years.%20The%20CRS%20was%20recalibrated%20to%20the%20present%20study%20cohort%20and%20compared%20with%20established%20atrial%20fibrillation-specific%20%28CHA2DS2-VASc%20and%20HAS-BLED%29%20and%20generalized%20%28Walter%20index%29%20risk%20scores.%20Cox%20proportional%20hazard%20models%20were%20used%20to%20assess%20the%20risk%20of%20mortality%20and%20discrimination%20was%20assessed%20by%20Harrel%20C-index.%20Among%20223%20patients%2C%20the%201-%20and%202-year%20mortality%20rates%20were%206.7%25%20and%2011.2%25%2C%20respectively.%20With%20the%20original%20CRS%2C%20only%20low%20BMI%20%28%26lt%3B23%5Cu00a0kg%5C%2Fm2%29%20was%20a%20significant%20predictor%20of%20all-cause%20mortality%20%28hazard%20ratio%20%5BHR%5D%20%5B95%25%20CI%5D%202.76%20%5B1.03%20to%207.35%5D%3B%20p%5Cu00a0%3D%5Cu00a00.04%29.%20With%20recalibration%2C%20BMI%20%26lt%3B29%5Cu00a0kg%5C%2Fm2%20and%20estimated%20glomerular%20filtration%20rate%20%26lt%3B60%5Cu00a0ml%5C%2Fmin%5C%2F1.73%5Cu00a0m2%20were%20significantly%20associated%20with%20an%20increased%20risk%20of%20death%20%28HR%20%5B95%25%20CI%5D%203.24%20%5B1.29%20to%208.13%5D%20and%202.48%20%5B1.07%20to%205.74%5D%2C%20respectively%29%2C%20with%20a%20trend%20toward%20significance%20noted%20for%20history%20of%20heart%20failure%20%28HR%20%5B95%25%20CI%5D%202.13%20%5B0.97%20to%204.67%5D%2C%20p%5Cu00a0%3D%5Cu00a00.06%29.%20Recalibration%20improved%20the%20discriminative%20ability%20of%20the%20CRS%20from%200.65%20to%200.70%20and%20significantly%20outperformed%20established%20risk%20scores%20%28CHA2DS2-VASc%5Cu00a0%3D%5Cu00a00.58%2C%20HAS-BLED%5Cu00a0%3D%5Cu00a00.55%2C%20Walter%20index%5Cu00a0%3D%5Cu00a00.62%29.%20In%20this%20single-center%2C%20observational%20study%2C%20the%20recalibrated%20CRS%20accurately%20risk%20stratified%20patients%20who%20underwent%20LAAO%20and%20significantly%20outperformed%20established%20atrial%20fibrillation-specific%20and%20generalized%20risk%20scores.%20In%20conclusion%2C%20clinical%20risk%20scores%20should%20be%20considered%20as%20an%20adjunct%20to%20standard%20of%20care%20when%20evaluating%20a%20patient%26%23039%3Bs%20candidacy%20for%20LAAO.%22%2C%22date%22%3A%222023-08-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.amjcard.2023.05.019%22%2C%22ISSN%22%3A%221879-1913%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MQPA457U%22%2C%22DYX9DYCW%22%2C%22MDMKKD23%22%2C%22Q5SGFS6G%22%2C%22B842TXVQ%22%2C%22PCL6ADRQ%22%2C%22TU4G2TDX%22%2C%22Q46ISS7S%22%2C%224U5B8N6T%22%5D%2C%22dateModified%22%3A%222023-07-21T19%3A10%3A02Z%22%7D%7D%2C%7B%22key%22%3A%2275TYSALW%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Raygor%20et%20al.%22%2C%22parsedDate%22%3A%222023-05-16%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRaygor%2C%20V.%2C%20Ayers%2C%20C.%2C%20%26lt%3Bstrong%26gt%3BSegar%26lt%3B%5C%2Fstrong%26gt%3B%2C%20M.%20W.%20et%20al.%20%282023%29.%20Impact%20of%20family%20history%20of%20premature%20coronary%20artery%20disease%20on%20noninvasive%20testing%20in%20stable%20chest%20pain.%20%26lt%3Bi%26gt%3BJ%20Am%20Heart%20Assoc%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B12%26lt%3B%5C%2Fi%26gt%3B%2C%20e029266.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FJAHA.122.029266%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FJAHA.122.029266%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20family%20history%20of%20premature%20coronary%20artery%20disease%20on%20noninvasive%20testing%20in%20stable%20chest%20pain%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Viraj%22%2C%22lastName%22%3A%22Raygor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Colby%22%2C%22lastName%22%3A%22Ayers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20W.%22%2C%22lastName%22%3A%22Segar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kartik%22%2C%22lastName%22%3A%22Agusala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amit%22%2C%22lastName%22%3A%22Khera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ambarish%22%2C%22lastName%22%3A%22Pandey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Parag%20H.%22%2C%22lastName%22%3A%22Joshi%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-05-16%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1161%5C%2FJAHA.122.029266%22%2C%22ISSN%22%3A%222047-9980%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22TU4G2TDX%22%2C%22X2D36SJL%22%2C%22NTAHPDUG%22%5D%2C%22dateModified%22%3A%222023-06-08T15%3A06%3A19Z%22%7D%7D%2C%7B%22key%22%3A%227EFFSVLE%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Khan%20et%20al.%22%2C%22parsedDate%22%3A%222023-05-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BKhan%2C%20M.%20S.%2C%20%26lt%3Bstrong%26gt%3BSegar%26lt%3B%5C%2Fstrong%26gt%3B%2C%20M.%20W.%2C%20Usman%2C%20M.%20S.%20et%20al.%20%282023%29.%20Effect%20of%20canagliflozin%20on%20heart%26%23xA0%3Bfailure%20hospitalization%20in%20diabetes%20according%20to%26%23xA0%3Bbaseline%20heart%26%23xA0%3Bfailure%20risk.%20%26lt%3Bi%26gt%3BJACC%20Heart%20Fail%26lt%3B%5C%2Fi%26gt%3B%2C%20S2213-1779%2823%2900186%26%23x2013%3B5.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2023.03.025%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2023.03.025%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effect%20of%20canagliflozin%20on%20heart%5Cu00a0failure%20hospitalization%20in%20diabetes%20according%20to%5Cu00a0baseline%20heart%5Cu00a0failure%20risk%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muhammad%20Shahzeb%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20W.%22%2C%22lastName%22%3A%22Segar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muhammad%20Shariq%22%2C%22lastName%22%3A%22Usman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kershaw%20V.%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harriette%20G.%20C.%22%2C%22lastName%22%3A%22Van%20Spall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adam%20D.%22%2C%22lastName%22%3A%22DeVore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muthiah%22%2C%22lastName%22%3A%22Vaduganathan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carolyn%20S.%20P.%22%2C%22lastName%22%3A%22Lam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiez%22%2C%22lastName%22%3A%22Zannad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Subodh%22%2C%22lastName%22%3A%22Verma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javed%22%2C%22lastName%22%3A%22Butler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20H.%20Wilson%22%2C%22lastName%22%3A%22Tang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ambarish%22%2C%22lastName%22%3A%22Pandey%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20In%20the%20CANVAS%20%28Canagliflozin%20Cardiovascular%20Assessment%20Study%29%20program%2C%20canagliflozin%20reduced%20the%20risk%20of%20heart%20failure%20%28HF%29%20hospitalization%20among%20individuals%20with%20type%202%20diabetes%20mellitus%20%28T2DM%29.%5CnOBJECTIVES%3A%20The%20purpose%20of%20this%20study%20was%20to%20evaluate%20heterogeneity%20in%20absolute%20and%20relative%20treatment%20effects%20of%5Cu00a0canagliflozin%20on%20HF%20hospitalization%20according%20to%20baseline%20HF%20risk%20as%20assessed%20by%20diabetes-specific%20HF%20risk%20scores%20%28WATCH-DM%20%5BWeight%20%28body%20mass%20index%29%2C%20Age%2C%20hyperTension%2C%20Creatinine%2C%20HDL-C%2C%20Diabetes%20control%20%28fasting%20plasma%20glucose%29%20and%20QRS%20Duration%2C%20MI%20and%20CABG%5D%20and%20TRS-HFDM%20%5BTIMI%20Risk%20Score%20for%20HF%20in%20Diabetes%5D%29.%5CnMETHODS%3A%20Participants%20in%20the%20CANVAS%20trial%20were%20categorized%20into%20low%2C%20medium%2C%20and%20high%20risk%20for%20HF%20using%20the%20WATCH-DM%20score%20%28for%20participants%20without%20prevalent%20HF%29%20and%20the%20TRS-HFDM%20score%20%28for%20all%20participants%29.%20The%20outcome%20of%20interest%20was%20time%20to%20first%20HF%20hospitalization.%20The%20treatment%20effect%20of%20canagliflozin%20vs%20placebo%20for%20HF%20hospitalization%20was%20compared%20across%20risk%20strata.%5CnRESULTS%3A%20Among%2010%2C137%20participants%20with%20available%20HF%20data%2C%201%2C446%20%2814.3%25%29%20had%20HF%20at%20baseline.%20Among%20participants%20without%20baseline%20HF%2C%20WATCH-DM%20risk%20category%20did%20not%20modify%20the%20treatment%20effect%20of%20canagliflozin%20%28vs%20placebo%29%20on%20HF%20hospitalization%20%28P%20interaction%5Cu00a0%3D%5Cu00a00.56%29.%20However%2C%20the%20absolute%20and%20relative%20risk%20reduction%20with%20canagliflozin%20was%20numerically%20greater%20in%20the%20high-risk%20group%20%28cumulative%20incidence%2C%20canagliflozin%20vs%20placebo%3A%208.1%25%20vs%2012.7%25%3B%20HR%3A%200.62%20%5B95%25%5Cu00a0CI%3A%200.37-0.93%5D%3B%20P%20%3D%200.03%3B%20number%20needed%20to%20treat%3A%2022%29%20than%20in%20the%20low-%20and%20intermediate-risk%20groups.%20When%20overall%20study%20participants%20were%20categorized%20according%20to%20the%20TRS-HFDM%20score%2C%20a%20statistically%20significant%20difference%20in%20the%20treatment%20effect%20of%20canagliflozin%20across%20risk%20strata%20was%20observed%20%28P%20interaction%5Cu00a0%3D%5Cu00a00.04%29.%20Canagliflozin%20significantly%20reduced%20the%20risk%20of%20HF%20hospitalization%20by%2039%25%20in%20the%20high-risk%20group%20%28HR%3A%200.61%20%5B95%25%5Cu00a0CI%3A%200.48-0.78%5D%3B%20P%5Cu00a0%26lt%3B%200.001%3B%20number%20needed%20to%20treat%3A%2020%29%20but%20not%20in%20the%20intermediate-%20or%20low-risk%20groups.%5CnCONCLUSIONS%3A%20Among%20participants%20with%20T2DM%2C%20the%20WATCH-DM%20and%20TRS-HFDM%20can%20reliably%20identify%20those%20at%20high%20risk%20for%20HF%20hospitalization%20and%20most%20likely%20to%20benefit%20from%20canagliflozin.%22%2C%22date%22%3A%222023-05-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jchf.2023.03.025%22%2C%22ISSN%22%3A%222213-1787%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22TU4G2TDX%22%2C%22X2D36SJL%22%2C%22NTAHPDUG%22%5D%2C%22dateModified%22%3A%222023-06-08T15%3A04%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22ZES99VKZ%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Khan%20et%20al.%22%2C%22parsedDate%22%3A%222023-04-15%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BKhan%2C%20M.%20S.%2C%20Singh%2C%20S.%2C%20%26lt%3Bstrong%26gt%3BSegar%26lt%3B%5C%2Fstrong%26gt%3B%2C%20M.%20W.%20et%20al.%20%282023%29.%20Polypharmacy%20and%20optimization%20of%20guideline-directed%20medical%20therapy%20in%20heart%20failure%3A%20The%20GUIDE-IT%20trial.%20%26lt%3Bi%26gt%3BJACC%20Heart%20Fail%26lt%3B%5C%2Fi%26gt%3B%2C%20S2213-1779%2823%2900137%26%23x2013%3B3.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2023.03.007%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2023.03.007%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Polypharmacy%20and%20optimization%20of%20guideline-directed%20medical%20therapy%20in%20heart%20failure%3A%20The%20GUIDE-IT%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muhammad%20Shahzeb%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sumitabh%22%2C%22lastName%22%3A%22Singh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20W.%22%2C%22lastName%22%3A%22Segar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muhammad%20Shariq%22%2C%22lastName%22%3A%22Usman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neil%22%2C%22lastName%22%3A%22Keshvani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20P.%22%2C%22lastName%22%3A%22Ambrosy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mona%22%2C%22lastName%22%3A%22Fiuzat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harriette%20G.%20C.%22%2C%22lastName%22%3A%22Van%20Spall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregg%20C.%22%2C%22lastName%22%3A%22Fonarow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiez%22%2C%22lastName%22%3A%22Zannad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20Michael%22%2C%22lastName%22%3A%22Felker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20L.%22%2C%22lastName%22%3A%22Januzzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%22%2C%22lastName%22%3A%22O%27Connor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javed%22%2C%22lastName%22%3A%22Butler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ambarish%22%2C%22lastName%22%3A%22Pandey%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Polypharmacy%20is%20common%20among%20patients%20with%20heart%20failure%20with%20reduced%20ejection%20fraction%20%28HFrEF%29.%20However%2C%20its%20impact%20on%20the%20use%20of%20optimal%20guideline-directed%20medical%20therapy%20%28GDMT%29%20is%20not%20well%20established.%5CnOBJECTIVES%3A%20This%20study%20sought%20to%20evaluate%20the%20association%20between%20polypharmacy%20and%20odds%20of%20receiving%20optimal%20GDMT%20over%20time%20among%20patients%20with%20HFrEF.%5CnMETHODS%3A%20The%20authors%20conducted%20a%20post%20hoc%20analysis%20of%20the%20GUIDE-IT%20%28Guiding%20Evidence-Based%20Therapy%20Using%20Biomarker%20Intensified%20Treatment%29%20trial.%20Polypharmacy%20was%20defined%20as%20receiving%5Cu00a0%5Cu22655%20medications%20%28excluding%20HFrEF%20GDMT%29%20at%20baseline.%20The%20outcome%20of%20interest%20was%20optimal%20triple%20therapy%20GDMT%20%28concurrent%20administration%20of%20a%20renin-angiotensin-aldosterone%20blocker%20and%20beta-blocker%20at%2050%25%20of%20the%20target%20dose%20and%20a%20mineralocorticoid%20receptor%20antagonist%20at%20any%20dose%29%20achieved%20over%20the%2012-month%20follow-up.%20Multivariable%20adjusted%20mixed-effect%20logistic%20regression%20models%20with%20multiplicative%20interaction%20terms%20%28time%5Cu00a0%5Cu00d7%20polypharmacy%29%20were%20constructed%20to%20evaluate%20how%20polypharmacy%20at%20baseline%20modified%20the%20odds%20of%20achieving%20optimal%20GDMT%20on%20follow-up.%5CnRESULTS%3A%20The%20study%20included%20891%20participants%20with%20HFrEF.%20The%20median%20number%20of%20non-GDMT%20medications%20at%20baseline%20was%204%20%28IQR%3A%203-6%29%2C%20with%20414%20%2846.5%25%29%20prescribed%5Cu00a0%5Cu22655%20and%20identified%20as%20being%20on%20polypharmacy.%20The%20proportion%20of%20participants%20who%20achieved%20optimal%20GDMT%20at%20the%20end%20of%20the%2012-month%20follow-up%20was%20lower%20with%20vs%20without%20polypharmacy%20at%20baseline%20%2815%25%20vs%2019%25%2C%20respectively%29.%20In%20adjusted%20mixed%20models%2C%20the%20odds%20of%20achieving%20optimal%20GDMT%20over%20time%20were%20modified%20by%20baseline%20polypharmacy%20status%20%28P-interaction%5Cu00a0%26lt%3B%5Cu00a00.001%29.%20Patients%20without%20polypharmacy%20at%20baseline%20had%20increased%20odds%20of%20achieving%20GDMT%20%28odds%20ratio%20%5BOR%5D%3A%201.16%20%5B95%25%5Cu00a0CI%3A%201.12-1.21%5D%20per%201-month%20increase%3B%20P%5Cu00a0%26lt%3B%200.001%29%20but%20not%20patients%20with%20polypharmacy%20%28OR%3A%201.01%20%5B95%25%5Cu00a0CI%3A%200.96-1.06%29%5D%20per%201-month%20increase%29.%5CnCONCLUSIONS%3A%20Patients%20with%20HFrEF%20who%20are%20on%20non-GDMT%20polypharmacy%20have%20lower%20odds%20of%20achieving%20optimal%20GDMT%20on%20follow-up.%22%2C%22date%22%3A%222023-04-15%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jchf.2023.03.007%22%2C%22ISSN%22%3A%222213-1787%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22TU4G2TDX%22%2C%22X2D36SJL%22%2C%22NTAHPDUG%22%5D%2C%22dateModified%22%3A%222023-06-08T17%3A55%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22C7X4LCE7%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Patel%20et%20al.%22%2C%22parsedDate%22%3A%222022-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPatel%2C%20K.%20V.%2C%20Khan%2C%20M.%20S.%2C%20%26lt%3Bstrong%26gt%3BSegar%26lt%3B%5C%2Fstrong%26gt%3B%2C%20M.%20W.%20et%20al.%20%282022%29.%20Optimal%20cardiometabolic%20health%20and%20risk%20of%20heart%20failure%20in%20type%202%20diabetes%3A%20an%20analysis%20from%20the%20Look%20AHEAD%20trial.%20%26lt%3Bi%26gt%3BEur%20J%20Heart%20Fail%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B24%26lt%3B%5C%2Fi%26gt%3B%2C%202037%26%23x2013%3B2047.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fejhf.2723%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fejhf.2723%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Optimal%20cardiometabolic%20health%20and%20risk%20of%20heart%20failure%20in%20type%202%20diabetes%3A%20an%20analysis%20from%20the%20Look%20AHEAD%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kershaw%20V.%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muhammad%20Shahzeb%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20W.%22%2C%22lastName%22%3A%22Segar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Judy%20L.%22%2C%22lastName%22%3A%22Bahnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katelyn%20R.%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeanne%20M.%22%2C%22lastName%22%3A%22Clark%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ashok%22%2C%22lastName%22%3A%22Balasubramanyam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%20G.%22%2C%22lastName%22%3A%22Bertoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muthiah%22%2C%22lastName%22%3A%22Vaduganathan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20E.%22%2C%22lastName%22%3A%22Farkouh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20L.%22%2C%22lastName%22%3A%22Januzzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Subodh%22%2C%22lastName%22%3A%22Verma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Espeland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ambarish%22%2C%22lastName%22%3A%22Pandey%22%7D%5D%2C%22abstractNote%22%3A%22AIMS%3A%20To%20evaluate%20the%20contribution%20of%20baseline%20and%20longitudinal%20changes%20in%20cardiometabolic%20health%20%28CMH%29%20towards%20heart%20failure%20%28HF%29%20risk%20among%20adults%20with%20type%202%20diabetes%20%28T2D%29.%5CnMETHODS%20AND%20RESULTS%3A%20Participants%20of%20the%20Look%20AHEAD%20trial%20with%20T2D%20and%20without%20prevalent%20HF%20were%20included.%20Adjusted%20Cox%20models%20were%20used%20to%20create%20a%20CMH%20score%20incorporating%20target%20levels%20of%20parameters%20weighted%20based%20on%20relative%20risk%20for%20HF.%20The%20associations%20of%20baseline%20and%20changes%20in%20the%20CMH%20score%20with%20risk%20of%20overall%20HF%2C%20HF%20with%20preserved%20%28HFpEF%29%20and%20reduced%20ejection%20fraction%20%28HFrEF%29%20were%20assessed%20using%20Cox%20models.%20Among%20the%205080%20participants%2C%20257%20incident%20HF%20events%20occurred%20over%2012.4%5Cu2009years%20of%20follow-up.%20The%20CMH%20score%20included%202%5Cu2009points%20each%20for%20target%20levels%20of%20waist%20circumference%2C%20glomerular%20filtration%20rate%2C%20urine%20albumin-to-creatinine%20ratio%2C%20and%201%5Cu2009point%20each%20for%20blood%20pressure%20and%20glycated%20haemoglobin%20at%20target.%20High%20baseline%20CMH%20score%20%286-8%29%20was%20significantly%20associated%20with%20lower%20overall%20HF%20risk%20%28adjusted%20hazard%20ratio%20%5BHR%5D%2C%20ref%5Cu00a0%3D%5Cu00a0low%20score%20%280-3%29%3A%200.31%2C%2095%25%20confidence%20interval%20%5BCI%5D%200.21-0.47%29%20with%20similar%20associations%20observed%20for%20HFpEF%20and%20HFrEF.%20Improvement%20in%20CMH%20was%20significantly%20associated%20with%20lower%20risk%20of%20overall%20HF%20%28adjusted%20HR%20per%201-unit%20increase%20in%20score%20at%204%5Cu2009years%3A%200.80%2C%2095%25%20CI%200.70-0.91%29.%20In%20the%20ACCORD%20validation%20cohort%2C%20the%20baseline%20CMH%20score%20performed%20well%20for%20predicting%20HF%20risk%20with%20adequate%20discrimination%20%28C-index%200.70%29%2C%20calibration%20%28chi-square%205.53%2C%20p%5Cu00a0%3D%5Cu00a00.70%29%2C%20and%20risk%20stratification%20%28adjusted%20HR%20%5Bhigh%20%286-8%29%20vs.%20low%20score%20%280-3%29%5D%3A%200.35%2C%2095%25%20CI%200.26-0.46%29.%20In%20the%20Look%20AHEAD%20subgroup%20with%20available%20biomarker%20data%2C%20incorporating%20N-terminal%20pro-B-type%20natriuretic%20peptide%20to%20the%20baseline%20CMH%20score%20improved%20model%20discrimination%20%28C-index%200.79%29%20and%20risk%20stratification%20%28adjusted%20HR%20%5Bhigh%20%288-10%29%20vs.%20low%20score%20%280-4%29%5D%3A%200.18%2C%2095%25%20CI%200.09-0.35%29.%5CnCONCLUSIONS%3A%20Achieving%20target%20levels%20of%20more%20CMH%20parameters%20at%20baseline%20and%20sustained%20improvements%20were%20associated%20with%20lower%20HF%20risk%20in%20T2D.%22%2C%22date%22%3A%22Nov%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fejhf.2723%22%2C%22ISSN%22%3A%221879-0844%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22TU4G2TDX%22%2C%22TXW6RMW4%22%5D%2C%22dateModified%22%3A%222023-01-06T17%3A14%3A19Z%22%7D%7D%2C%7B%22key%22%3A%223JJG8N73%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Segar%20et%20al.%22%2C%22parsedDate%22%3A%222022-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bstrong%26gt%3BSegar%26lt%3B%5C%2Fstrong%26gt%3B%2C%20M.%20W.%2C%20Keshvani%2C%20N.%2C%20Rao%2C%20S.%20et%20al.%20%282022%29.%20Race%2C%20social%20determinants%20of%20health%2C%20and%20length%20of%20stay%20among%20hospitalized%20patients%20with%20heart%20failure%3A%20An%20analysis%20from%20the%20get%20with%20the%20guidelines-heart%20failure%20registry.%20%26lt%3Bi%26gt%3BCirc%20Heart%20Fail%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B15%26lt%3B%5C%2Fi%26gt%3B%2C%20e009401.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FCIRCHEARTFAILURE.121.009401%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FCIRCHEARTFAILURE.121.009401%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Race%2C%20social%20determinants%20of%20health%2C%20and%20length%20of%20stay%20among%20hospitalized%20patients%20with%20heart%20failure%3A%20An%20analysis%20from%20the%20get%20with%20the%20guidelines-heart%20failure%20registry%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20W.%22%2C%22lastName%22%3A%22Segar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neil%22%2C%22lastName%22%3A%22Keshvani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shreya%22%2C%22lastName%22%3A%22Rao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregg%20C.%22%2C%22lastName%22%3A%22Fonarow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandeep%20R.%22%2C%22lastName%22%3A%22Das%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ambarish%22%2C%22lastName%22%3A%22Pandey%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Racial%20disparities%20in%20heart%20failure%20hospitalization%20and%20mortality%20are%20well%20established%3B%20however%2C%20the%20association%20between%20different%20social%20determinants%20of%20health%20%28SDOH%29%20and%20length%20of%20stay%20%28LOS%29%20and%20the%20extent%20to%20which%20this%20association%20may%20differ%20across%20racial%20groups%20is%20not%20well%20established.%5CnMETHODS%3A%20We%20utilized%20data%20from%20the%20Get%20With%20The%20Guidelines-Heart%20Failure%20registry%20to%20evaluate%20the%20association%20between%20SDOH%2C%20as%20determined%20by%20patients%26%23039%3B%20residential%20ZIP%20Code%20and%20LOS%20among%20patients%20hospitalized%20with%20heart%20failure.%20We%20also%20assessed%20the%20race-specific%20contribution%20of%20the%20ZIP%20Code-level%20SDOH%20to%20LOS%20in%20patients%20of%20Black%20and%20non-Black%20races.%20Finally%2C%20we%20evaluated%20SDOH%20predictors%20of%20racial%20differences%20in%20LOS%20at%20the%20hospital%20level.%5CnRESULTS%3A%20Among%20301%5Cu2009500%20patients%20%2820.2%25%20Black%20race%29%2C%20the%20median%20LOS%20was%204%20days.%20In%20adjusted%20analysis%20accounting%20for%20patient-level%20and%20hospital-level%20factors%2C%20SDOH%20parameters%20of%20education%2C%20income%2C%20housing%20instability%2C%20and%20foreign-born%20were%20significantly%20associated%20with%20LOS%20after%20adjusting%20for%20clinical%20status%20and%20hospital-level%20factors.%20SDOH%20parameters%20accounted%20for%2025.8%25%20of%20the%20total%20attributable%20risk%20for%20prolonged%20LOS%20among%20Black%20patients%20compared%20with%2010.1%25%20in%20patients%20of%20non-Black%20race.%20Finally%2C%20hospitals%20with%20disproportionately%20longer%20LOS%20for%20Black%20versus%20non-Black%20patients%20were%20more%20likely%20to%20care%20for%20disadvantaged%20patients%20living%20in%20ZIP%20Codes%20with%20a%20higher%20percentage%20of%20foreign-born%20and%20non-English%20speaking%20areas.%5CnCONCLUSIONS%3A%20ZIP%20Code-level%20SDOH%20markers%20can%20identify%20patients%20at%20risk%20for%20prolonged%20LOS%2C%20and%20the%20effects%20of%20SDOH%20parameters%20are%20significantly%20greater%20among%20Black%20adults%20with%20heart%20failure%20as%20compared%20with%20non-Black%20adults.%22%2C%22date%22%3A%22Nov%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCHEARTFAILURE.121.009401%22%2C%22ISSN%22%3A%221941-3297%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22TU4G2TDX%22%2C%22QF52JASW%22%5D%2C%22dateModified%22%3A%222022-12-01T19%3A19%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22JGMXJPSD%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Stevens%20et%20al.%22%2C%22parsedDate%22%3A%222022-08-27%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BStevens%2C%20S.%20R.%2C%20%26lt%3Bstrong%26gt%3BSegar%26lt%3B%5C%2Fstrong%26gt%3B%2C%20M.%20W.%2C%20Pandey%2C%20A.%20et%20al.%20%282022%29.%20Development%20and%20validation%20of%20a%20model%20to%20predict%20cardiovascular%20death%2C%20nonfatal%20myocardial%20infarction%2C%20or%20nonfatal%20stroke%20in%20patients%20with%20type%202%20diabetes%20mellitus%20and%20established%20atherosclerotic%20cardiovascular%20disease.%20%26lt%3Bi%26gt%3BCardiovasc%20Diabetol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B21%26lt%3B%5C%2Fi%26gt%3B%2C%20166.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12933-022-01603-8%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12933-022-01603-8%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Development%20and%20validation%20of%20a%20model%20to%20predict%20cardiovascular%20death%2C%20nonfatal%20myocardial%20infarction%2C%20or%20nonfatal%20stroke%20in%20patients%20with%20type%202%20diabetes%20mellitus%20and%20established%20atherosclerotic%20cardiovascular%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susanna%20R.%22%2C%22lastName%22%3A%22Stevens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20W.%22%2C%22lastName%22%3A%22Segar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ambarish%22%2C%22lastName%22%3A%22Pandey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuliya%22%2C%22lastName%22%3A%22Lokhnygina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20B.%22%2C%22lastName%22%3A%22Green%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darren%20K.%22%2C%22lastName%22%3A%22McGuire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eberhard%22%2C%22lastName%22%3A%22Standl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%20D.%22%2C%22lastName%22%3A%22Peterson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rury%20R.%22%2C%22lastName%22%3A%22Holman%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Among%20individuals%20with%20atherosclerotic%20cardiovascular%20disease%20%28ASCVD%29%2C%20type%202%20diabetes%20mellitus%20%28T2DM%29%20is%20common%20and%20confers%20increased%20risk%20for%20morbidity%20and%20mortality.%20Differentiating%20risk%20is%20key%20to%20optimize%20efficiency%20of%20treatment%20selection.%20Our%20objective%20was%20to%20develop%20and%20validate%20a%20model%20to%20predict%20risk%20of%20major%20adverse%20cardiovascular%20events%20%28MACE%29%20comprising%20the%20first%20event%20of%20cardiovascular%20death%2C%20myocardial%20infarction%20%28MI%29%2C%20or%20stroke%20for%20individuals%20with%20both%20T2DM%20and%20ASCVD.%5CnMETHODS%3A%20Using%20data%20from%20the%20Trial%20Evaluating%20Cardiovascular%20Outcomes%20with%20Sitagliptin%20%28TECOS%29%2C%20we%20used%20Cox%20proportional%20hazards%20models%20to%20predict%20MACE%20among%20participants%20with%20T2DM%20and%20ASCVD.%20All%20baseline%20covariates%20collected%20in%20the%20trial%20were%20considered%20for%20inclusion%2C%20although%20some%20were%20excluded%20immediately%20because%20of%20large%20missingness%20or%20collinearity.%20A%20full%20model%20was%20developed%20using%20stepwise%20selection%20in%20each%20of%2025%20imputed%20datasets%2C%20and%20comprised%20candidate%20variables%20selected%20in%2020%20of%20the%2025%20datasets.%20A%20parsimonious%20model%20with%20a%20maximum%20of%2010%20degrees%20of%20freedom%20was%20created%20using%20Cox%20models%20with%20least%20absolute%20shrinkage%20and%20selection%20operator%20%28LASSO%29%2C%20where%20the%20adjusted%20R-square%20was%20used%20as%20criterion%20for%20selection.%20The%20model%20was%20then%20externally%20validated%20among%20a%20cohort%20of%20participants%20with%20similar%20criteria%20in%20the%20ACCORD%20%28Action%20to%20Control%20Cardiovascular%20Risk%20in%20Diabetes%29%20trial.%20Discrimination%20of%20both%20models%20was%20assessed%20using%20Harrell%26%23039%3Bs%20C-index%20and%20model%20calibration%20by%20the%20Greenwood-Nam-D%26%23039%3BAgostino%20statistic%20based%20on%204-year%20event%20rates.%5CnRESULTS%3A%20Overall%2C%201491%20%2810.2%25%29%20of%2014%2C671%20participants%20in%20TECOS%20and%20130%20%289.3%25%29%20in%20the%20ACCORD%20validation%20cohort%20%28n%5Cu2009%3D%5Cu20091404%29%20had%20MACE%20over%203%20years%26%23039%3B%20median%20follow-up.%20The%20final%20model%20included%209%20characteristics%20%28prior%20stroke%2C%20age%2C%20chronic%20kidney%20disease%2C%20prior%20MI%2C%20sex%2C%20heart%20failure%2C%20insulin%20use%2C%20atrial%20fibrillation%2C%20and%20microvascular%20complications%29.%20The%20model%20had%20moderate%20discrimination%20in%20both%20the%20internal%20and%20external%20validation%20samples%20%28C-index%5Cu2009%3D%5Cu20090.65%20and%200.61%2C%20respectively%29.%20The%20model%20was%20well%20calibrated%20across%20the%20risk%20spectrum-from%20a%20cumulative%20MACE%20rate%20of%206%25%20at%204%20years%20in%20the%20lowest%20risk%20quintile%20to%2026%25%20in%20the%20highest%20risk%20quintile.%5CnCONCLUSION%3A%20Among%20patients%20with%20T2DM%20and%20prevalent%20ASCVD%2C%20this%209-factor%20risk%20model%20can%20quantify%20the%20risk%20of%20future%20ASCVD%20complications%20and%20inform%20decision%20making%20for%20treatments%20and%20intensity.%22%2C%22date%22%3A%22Aug%2027%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12933-022-01603-8%22%2C%22ISSN%22%3A%221475-2840%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22TU4G2TDX%22%2C%22X2D36SJL%22%2C%22VTWWYEIB%22%5D%2C%22dateModified%22%3A%222022-09-02T20%3A11%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22996SACHG%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Shah%20et%20al.%22%2C%22parsedDate%22%3A%222022-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BShah%2C%20S.%2C%20%26lt%3Bstrong%26gt%3BSegar%26lt%3B%5C%2Fstrong%26gt%3B%2C%20M.%20W.%2C%20Kondamudi%2C%20N.%20et%20al.%20%282022%29.%20Supranormal%20left%20ventricular%20ejection%20fraction%2C%20stroke%20volume%2C%20and%20cardiovascular%20risk%3A%20Findings%20from%20population-based%20cohort%20studies.%20%26lt%3Bi%26gt%3BJACC%20Heart%20Fail%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B10%26lt%3B%5C%2Fi%26gt%3B%2C%20583%26%23x2013%3B594.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2022.05.007%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2022.05.007%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Supranormal%20left%20ventricular%20ejection%20fraction%2C%20stroke%20volume%2C%20and%20cardiovascular%20risk%3A%20Findings%20from%20population-based%20cohort%20studies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonia%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20W.%22%2C%22lastName%22%3A%22Segar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nitin%22%2C%22lastName%22%3A%22Kondamudi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Colby%22%2C%22lastName%22%3A%22Ayers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvin%22%2C%22lastName%22%3A%22Chandra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susan%22%2C%22lastName%22%3A%22Matulevicius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kartik%22%2C%22lastName%22%3A%22Agusala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ron%22%2C%22lastName%22%3A%22Peshock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suhny%22%2C%22lastName%22%3A%22Abbara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erin%20D.%22%2C%22lastName%22%3A%22Michos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20H.%22%2C%22lastName%22%3A%22Drazner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joao%20A.%20C.%22%2C%22lastName%22%3A%22Lima%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20T.%22%2C%22lastName%22%3A%22Longstreth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ambarish%22%2C%22lastName%22%3A%22Pandey%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Supranormal%20ejection%20fraction%20by%20echocardiography%20in%20clinically%20referred%20patient%20populations%20has%20been%20associated%20with%20an%20increased%20risk%20of%20cardiovascular%20disease%20%28CVD%29.%20The%20prognostic%20implication%20of%20supranormal%20left%20ventricular%20ejection%20fraction%20%28LVEF%29-assessed%20by%20cardiac%20magnetic%20resonance%20%28CMR%29-in%20healthy%2C%20community-dwelling%20individuals%20is%20unknown.%5CnOBJECTIVES%3A%20The%20purpose%20of%20this%20study%20is%20to%20investigate%20the%20prognostic%20implication%20of%20supranormal%20LVEF%20as%20assessed%20by%20CMR%20and%20its%20inter-relationship%20with%20stroke%20volume%20among%20community-dwelling%20adults%20without%20CVD.%5CnMETHODS%3A%20Participants%20from%20the%20MESA%20%28Multi-Ethnic%20Study%20of%20Atherosclerosis%29%20and%20DHS%20%28Dallas%20Heart%20Study%29%20cohorts%20free%20of%20CVD%20who%20underwent%20CMR%20with%20LVEF%20above%20the%20normal%20CMR%20cutoff%20%28%5Cu226557%25%29%20were%20included.%20The%20association%20between%20cohort-specific%20LVEF%20categories%20and%20risk%20of%20clinically%20adjudicated%20major%20adverse%20cardiovascular%20events%20%28MACE%29%20was%20assessed%20using%20adjusted%20Cox%20models.%20Subgroup%20analysis%20was%20also%20performed%20to%20evaluate%20the%20association%20of%20LVEF%20and%20risk%20of%20MACE%20among%20individuals%20stratified%20by%20left%20ventricular%20stroke%20volume%20index.%5CnRESULTS%3A%20The%20study%20included%204%2C703%20participants%20from%20MESA%20and%202%2C287%20from%20DHS%20with%20727%20and%20151%20MACE%20events%2C%20respectively.%20In%20adjusted%20Cox%20models%2C%20the%20risk%20of%20MACE%20was%20highest%20among%20individuals%20in%20LVEF%20Q4%20%28vs%20Q1%29%20in%20both%20cohorts%20after%20accounting%20for%20potential%20confounders%20%28MESA%3A%20HR%20%3D%201.27%20%5B95%25%20CI%3A%201.01-1.60%5D%2C%20P%20%3D%200.04%3B%20DHS%3A%20HR%20%3D%201.72%20%5B95%25%20CI%3A%201.05-2.79%5D%2C%20P%20%3D%200.03%29.%20A%20significant%20interaction%20was%20found%20between%20the%20continuous%20measures%20of%20LVEF%20and%20left%20ventricular%20stroke%20volume%20index%20%28P%20interaction%5Cu00a0%3D%5Cu00a00.02%29%20such%20that%20higher%20LVEF%20was%20significantly%20associated%20with%20an%20increased%20risk%20of%20MACE%20among%20individuals%20with%20low%20but%20not%20high%20stroke%20volume.%5CnCONCLUSIONS%3A%20Among%20community-dwelling%20adults%20without%20CVD%2C%20LVEF%20in%20the%20supranormal%20range%20is%20associated%20with%20a%20higher%20risk%20of%20adverse%20cardiovascular%20outcomes%2C%20particularly%20in%20those%20with%20lower%20stroke%20volume.%22%2C%22date%22%3A%22Aug%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jchf.2022.05.007%22%2C%22ISSN%22%3A%222213-1787%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22TU4G2TDX%22%2C%22X2D36SJL%22%2C%22VTWWYEIB%22%5D%2C%22dateModified%22%3A%222022-09-02T20%3A15%3A06Z%22%7D%7D%2C%7B%22key%22%3A%226YYYJ685%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Segar%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bstrong%26gt%3BSegar%26lt%3B%5C%2Fstrong%26gt%3B%2C%20M.%20W.%2C%20Hall%2C%20J.%20L.%2C%20Jhund%2C%20P.%20S.%20et%20al.%20%282022%29.%20Machine%20learning-based%20models%20incorporating%20social%20determinants%20of%20health%20vs%20traditional%20models%20for%20predicting%20in-hospital%20mortality%20in%20patients%20with%20heart%20failure.%20%26lt%3Bi%26gt%3BJAMA%20Cardiol%26lt%3B%5C%2Fi%26gt%3B.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1001%5C%2Fjamacardio.2022.1900%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1001%5C%2Fjamacardio.2022.1900%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Machine%20learning-based%20models%20incorporating%20social%20determinants%20of%20health%20vs%20traditional%20models%20for%20predicting%20in-hospital%20mortality%20in%20patients%20with%20heart%20failure%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20W.%22%2C%22lastName%22%3A%22Segar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20L.%22%2C%22lastName%22%3A%22Hall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pardeep%20S.%22%2C%22lastName%22%3A%22Jhund%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tiffany%20M.%22%2C%22lastName%22%3A%22Powell-Wiley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alanna%20A.%22%2C%22lastName%22%3A%22Morris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Kao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregg%20C.%22%2C%22lastName%22%3A%22Fonarow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rosalba%22%2C%22lastName%22%3A%22Hernandez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nasrien%20E.%22%2C%22lastName%22%3A%22Ibrahim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Rutan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ann%20Marie%22%2C%22lastName%22%3A%22Navar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%20M.%22%2C%22lastName%22%3A%22Stevens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ambarish%22%2C%22lastName%22%3A%22Pandey%22%7D%5D%2C%22abstractNote%22%3A%22Importance%3A%20Traditional%20models%20for%20predicting%20in-hospital%20mortality%20for%20patients%20with%20heart%20failure%20%28HF%29%20have%20used%20logistic%20regression%20and%20do%20not%20account%20for%20social%20determinants%20of%20health%20%28SDOH%29.%5CnObjective%3A%20To%20develop%20and%20validate%20novel%20machine%20learning%20%28ML%29%20models%20for%20HF%20mortality%20that%20incorporate%20SDOH.%5CnDesign%2C%20Setting%2C%20and%20Participants%3A%20This%20retrospective%20study%20used%20the%20data%20from%20the%20Get%20With%20The%20Guidelines-Heart%20Failure%20%28GWTG-HF%29%20registry%20to%20identify%20HF%20hospitalizations%20between%20January%201%2C%202010%2C%20and%20December%2031%2C%202020.%20The%20study%20included%20patients%20with%20acute%20decompensated%20HF%20who%20were%20hospitalized%20at%20the%20GWTG-HF%20participating%20centers%20during%20the%20study%20period.%20Data%20analysis%20was%20performed%20January%206%2C%202021%2C%20to%20April%2026%2C%202022.%20External%20validation%20was%20performed%20in%20the%20hospitalization%20cohort%20from%20the%20Atherosclerosis%20Risk%20in%20Communities%20%28ARIC%29%20study%20between%202005%20and%202014.%5CnMain%20Outcomes%20and%20Measures%3A%20Random%20forest-based%20ML%20approaches%20were%20used%20to%20develop%20race-specific%20and%20race-agnostic%20models%20for%20predicting%20in-hospital%20mortality.%20Performance%20was%20assessed%20using%20C%20index%20%28discrimination%29%2C%20regression%20slopes%20for%20observed%20vs%20predicted%20mortality%20rates%20%28calibration%29%2C%20and%20decision%20curves%20for%20prognostic%20utility.%5CnResults%3A%20The%20training%20data%20set%20included%20123%5Cu202f634%20hospitalized%20patients%20with%20HF%20who%20were%20enrolled%20in%20the%20GWTG-HF%20registry%20%28mean%20%5BSD%5D%20age%2C%2071%20%5B13%5D%20years%3B%2058%5Cu202f356%20%5B47.2%25%5D%20female%20individuals%3B%2065%5Cu202f278%20%5B52.8%25%5D%20male%20individuals.%20Patients%20were%20analyzed%20in%202%20categories%3A%20Black%20%2823%5Cu202f453%20%5B19.0%25%5D%29%20and%20non-Black%20%282121%20%5B2.1%25%5D%20Asian%3B%2091%5Cu202f154%20%5B91.0%25%5D%20White%2C%20and%206906%20%5B6.9%25%5D%20other%20race%20and%20ethnicity%29.%20The%20ML%20models%20demonstrated%20excellent%20performance%20in%20the%20internal%20testing%20subset%20%28n%5Cu2009%3D%5Cu200982%5Cu202f420%29%20%28C%20statistic%2C%200.81%20for%20Black%20patients%20and%200.82%20for%20non-Black%20patients%29%20and%20in%20the%20real-world-like%20cohort%20with%20less%20than%2050%25%20missingness%20on%20covariates%20%28n%5Cu2009%3D%5Cu2009553%5Cu202f506%3B%20C%20statistic%2C%200.74%20for%20Black%20patients%20and%200.75%20for%20non-Black%20patients%29.%20In%20the%20external%20validation%20cohort%20%28ARIC%20registry%3B%20n%5Cu2009%3D%5Cu20091205%20Black%20patients%20and%202264%20non-Black%20patients%29%2C%20ML%20models%20demonstrated%20high%20discrimination%20and%20adequate%20calibration%20%28C%20statistic%2C%200.79%20and%200.80%2C%20respectively%29.%20Furthermore%2C%20the%20performance%20of%20the%20ML%20models%20was%20superior%20to%20the%20traditional%20GWTG-HF%20risk%20score%20model%20%28C%20index%2C%200.69%20for%20both%20race%20groups%29%20and%20other%20rederived%20logistic%20regression%20models%20using%20race%20as%20a%20covariate.%20The%20performance%20of%20the%20ML%20models%20was%20identical%20using%20the%20race-specific%20and%20race-agnostic%20approaches%20in%20the%20GWTG-HF%20and%20external%20validation%20cohorts.%20In%20the%20GWTG-HF%20cohort%2C%20the%20addition%20of%20zip%20code-level%20SDOH%20parameters%20to%20the%20ML%20model%20with%20clinical%20covariates%20only%20was%20associated%20with%20better%20discrimination%2C%20prognostic%20utility%20%28assessed%20using%20decision%20curves%29%2C%20and%20model%20reclassification%20metrics%20in%20Black%20patients%20%28net%20reclassification%20improvement%2C%200.22%20%5B95%25%20CI%2C%200.14-0.30%5D%3B%20P%5Cu2009%26lt%3B%5Cu2009.001%29%20but%20not%20in%20non-Black%20patients.%5CnConclusions%20and%20Relevance%3A%20ML%20models%20for%20HF%20mortality%20demonstrated%20superior%20performance%20to%20the%20traditional%20and%20rederived%20logistic%20regressions%20models%20using%20race%20as%20a%20covariate.%20The%20addition%20of%20SDOH%20parameters%20improved%20the%20prognostic%20utility%20of%20prediction%20models%20in%20Black%20patients%20but%20not%20non-Black%20patients%20in%20the%20GWTG-HF%20registry.%22%2C%22date%22%3A%22July%2006%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1001%5C%2Fjamacardio.2022.1900%22%2C%22ISSN%22%3A%222380-6591%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22TU4G2TDX%22%2C%22X2D36SJL%22%2C%222RCWVZ4F%22%5D%2C%22dateModified%22%3A%222022-08-02T14%3A41%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22JDCI6ZY2%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Segar%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bstrong%26gt%3BSegar%26lt%3B%5C%2Fstrong%26gt%3B%2C%20M.%20W.%2C%20Patel%2C%20K.%20V.%2C%20Hellkamp%2C%20A.%20S.%20et%20al.%20%282022%29.%20Validation%20of%20the%20WATCH-DM%20and%20TRS-HFDM%20Risk%20Scores%20to%20Predict%20the%20Risk%20of%20Incident%20Hospitalization%20for%20Heart%20Failure%20Among%20Adults%20With%20Type%202%20Diabetes%3A%20A%20Multicohort%20Analysis.%20%26lt%3Bi%26gt%3BJ%20Am%20Heart%20Assoc%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B11%26lt%3B%5C%2Fi%26gt%3B%2C%20e024094.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FJAHA.121.024094%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FJAHA.121.024094%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Validation%20of%20the%20WATCH-DM%20and%20TRS-HFDM%20Risk%20Scores%20to%20Predict%20the%20Risk%20of%20Incident%20Hospitalization%20for%20Heart%20Failure%20Among%20Adults%20With%20Type%202%20Diabetes%3A%20A%20Multicohort%20Analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20W.%22%2C%22lastName%22%3A%22Segar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kershaw%20V.%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%20S.%22%2C%22lastName%22%3A%22Hellkamp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muthiah%22%2C%22lastName%22%3A%22Vaduganathan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuliya%22%2C%22lastName%22%3A%22Lokhnygina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20B.%22%2C%22lastName%22%3A%22Green%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Siu-Hin%22%2C%22lastName%22%3A%22Wan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmed%20A.%22%2C%22lastName%22%3A%22Kolkailah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rury%20R.%22%2C%22lastName%22%3A%22Holman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%20D.%22%2C%22lastName%22%3A%22Peterson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vaishnavi%22%2C%22lastName%22%3A%22Kannan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Duwayne%20L.%22%2C%22lastName%22%3A%22Willett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darren%20K.%22%2C%22lastName%22%3A%22McGuire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ambarish%22%2C%22lastName%22%3A%22Pandey%22%7D%5D%2C%22abstractNote%22%3A%22Background%20The%20WATCH-DM%20%28weight%20%5Bbody%20mass%20index%5D%2C%20age%2C%20hypertension%2C%20creatinine%2C%20high-density%20lipoprotein%20cholesterol%2C%20diabetes%20control%20%5Bfasting%20plasma%20glucose%5D%2C%20ECG%20QRS%20duration%2C%20myocardial%20infarction%2C%20and%20coronary%20artery%20bypass%20grafting%29%20and%20TRS-HFDM%20%28Thrombolysis%20in%20Myocardial%20Infarction%20%5BTIMI%5D%20risk%20score%20for%20heart%20failure%20in%20diabetes%29%20risk%20scores%20were%20developed%20to%20predict%20risk%20of%20heart%20failure%20%28HF%29%20among%20individuals%20with%20type%202%20diabetes.%20WATCH-DM%20was%20developed%20to%20predict%20incident%20HF%2C%20whereas%20TRS-HFDM%20predicts%20HF%20hospitalization%20among%20patients%20with%20and%20without%20a%20prior%20HF%20history.%20We%20evaluated%20the%20model%20performance%20of%20both%20scores%20to%20predict%20incident%20HF%20events%20among%20patients%20with%20type%202%20diabetes%20and%20no%20history%20of%20HF%20hospitalization%20across%20different%20cohorts%20and%20clinical%20settings%20with%20varying%20baseline%20risk.%20Methods%20and%20Results%20Incident%20HF%20risk%20was%20estimated%20by%20the%20integer-based%20WATCH-DM%20and%20TRS-HFDM%20scores%20in%20participants%20with%20type%202%20diabetes%20free%20of%20baseline%20HF%20from%202%20randomized%20clinical%20trials%20%28TECOS%20%5BTrial%20Evaluating%20Cardiovascular%20Outcomes%20With%20Sitagliptin%5D%2C%20N%3D12%5Cu00a0028%3B%20and%20Look%20AHEAD%20%5BLook%20Action%20for%20Health%20in%20Diabetes%5D%20trial%2C%20N%3D4867%29.%20The%20integer-based%20WATCH-DM%20score%20was%20also%20validated%20in%20electronic%20health%20record%20data%20from%20a%20single%20large%20health%20care%20system%20%28N%3D7475%29.%20Model%20discrimination%20was%20assessed%20by%20the%20Harrell%20concordance%20index%20and%20calibration%20by%20the%20Greenwood-Nam-D%26%23039%3BAgostino%20statistic.%20HF%20incidence%20rate%20was%207.5%2C%203.9%2C%20and%204.1%20per%201000%20person-years%20in%20the%20TECOS%2C%20Look%20AHEAD%20trial%2C%20and%20electronic%20health%20record%20cohorts%2C%20respectively.%20Integer-based%20WATCH-DM%20and%20TRS-HFDM%20scores%20had%20similar%20discrimination%20and%20calibration%20for%20predicting%205-year%20HF%20risk%20in%20the%20Look%20AHEAD%20trial%20cohort%20%28concordance%20indexes%3D0.70%3B%20Greenwood-Nam-D%26%23039%3BAgostino%20P%26gt%3B0.30%20for%20both%29.%20Both%20scores%20had%20lower%20discrimination%20and%20underpredicted%20HF%20risk%20in%20the%20TECOS%20cohort%20%28concordance%20indexes%3D0.65%20and%200.66%2C%20respectively%3B%20Greenwood-Nam-D%26%23039%3BAgostino%20P%26lt%3B0.001%20for%20both%29.%20In%20the%20electronic%20health%20record%20cohort%2C%20the%20integer-based%20WATCH-DM%20score%20demonstrated%20a%20concordance%20index%20of%200.73%20with%20adequate%20calibration%20%28Greenwood-Nam-D%26%23039%3BAgostino%20P%3D0.96%29.%20TRS-HFDM%20score%20could%20not%20be%20validated%20in%20the%20electronic%20health%20record%20because%20of%20unavailability%20of%20data%20on%20urine%20albumin%5C%2Fcreatinine%20ratio%20in%20most%20patients%20in%20the%20contemporary%20clinical%20practice.%20Conclusions%20The%20WATCH-DM%20and%20TRS-HFDM%20risk%20scores%20can%20discriminate%20risk%20of%20HF%20among%20intermediate-risk%20populations%20with%20type%202%20diabetes.%22%2C%22date%22%3A%22June%2007%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1161%5C%2FJAHA.121.024094%22%2C%22ISSN%22%3A%222047-9980%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22TU4G2TDX%22%2C%22X2D36SJL%22%2C%22ZSY78DJL%22%5D%2C%22dateModified%22%3A%222022-07-06T19%3A07%3A30Z%22%7D%7D%5D%7D
Segar, M. W., Zhang, A., Paisley, R. D. et al. (2023). Risk stratification in patients who underwent percutaneous left atrial appendage occlusion. Am J Cardiol 200, 50–56. https://doi.org/10.1016/j.amjcard.2023.05.019.
Raygor, V., Ayers, C., Segar, M. W. et al. (2023). Impact of family history of premature coronary artery disease on noninvasive testing in stable chest pain. J Am Heart Assoc 12, e029266. https://doi.org/10.1161/JAHA.122.029266.
Khan, M. S., Segar, M. W., Usman, M. S. et al. (2023). Effect of canagliflozin on heart failure hospitalization in diabetes according to baseline heart failure risk. JACC Heart Fail, S2213-1779(23)00186–5. https://doi.org/10.1016/j.jchf.2023.03.025.
Khan, M. S., Singh, S., Segar, M. W. et al. (2023). Polypharmacy and optimization of guideline-directed medical therapy in heart failure: The GUIDE-IT trial. JACC Heart Fail, S2213-1779(23)00137–3. https://doi.org/10.1016/j.jchf.2023.03.007.
Patel, K. V., Khan, M. S., Segar, M. W. et al. (2022). Optimal cardiometabolic health and risk of heart failure in type 2 diabetes: an analysis from the Look AHEAD trial. Eur J Heart Fail 24, 2037–2047. https://doi.org/10.1002/ejhf.2723.
Segar, M. W., Keshvani, N., Rao, S. et al. (2022). Race, social determinants of health, and length of stay among hospitalized patients with heart failure: An analysis from the get with the guidelines-heart failure registry. Circ Heart Fail 15, e009401. https://doi.org/10.1161/CIRCHEARTFAILURE.121.009401.
Stevens, S. R., Segar, M. W., Pandey, A. et al. (2022). Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease. Cardiovasc Diabetol 21, 166. https://doi.org/10.1186/s12933-022-01603-8.
Shah, S., Segar, M. W., Kondamudi, N. et al. (2022). Supranormal left ventricular ejection fraction, stroke volume, and cardiovascular risk: Findings from population-based cohort studies. JACC Heart Fail 10, 583–594. https://doi.org/10.1016/j.jchf.2022.05.007.
Segar, M. W., Hall, J. L., Jhund, P. S. et al. (2022). Machine learning-based models incorporating social determinants of health vs traditional models for predicting in-hospital mortality in patients with heart failure. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2022.1900.
Segar, M. W., Patel, K. V., Hellkamp, A. S. et al. (2022). Validation of the WATCH-DM and TRS-HFDM Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis. J Am Heart Assoc 11, e024094. https://doi.org/10.1161/JAHA.121.024094.

Recent News

See All

New Insights Into Heart Disease Risk for Houston Area Women

Houston HeartReach Study Examines Cardiometabolic Risk Factors for This Diverse Group Cardiovascular disease is the leading cause of death for...

Read more

Dr. Matthew Segar Recognized With DEI Abstract Award From Heart Rhythm Society

Novel Machine Learning Model Improves Prediction of Atrial Fibrillation Risk   The Heart Rhythm Society recently recognized Matthew Segar, MD,...

Read more

Fellow Dr. Matthew Segar Contributes to Online Resource for Cardiologists

Matthew Segar, MD, MS, a third-year fellow in The Texas Heart Institute Cardiovascular Disease Fellowship at Baylor St. Luke’s Medical...

Read more